{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T13:20:00Z","timestamp":1785590400372,"version":"3.56.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T00:00:00Z","timestamp":1534550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Nippon Shinyaku Co., Ltd, Kyoto, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00345-018-2453-x","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T12:15:49Z","timestamp":1534594549000},"page":"867-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7823-2600","authenticated-orcid":false,"given":"Yoshihisa","family":"Matsukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Majima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Sassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokunori","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momokazu","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,18]]},"reference":[{"key":"2453_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/iju.13401","volume":"24","author":"Y Homma","year":"2017","unstructured":"Homma Y, Gotoh M, Kawauchi A et al (2017) Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 24:716\u2013729","journal-title":"Int J Urol"},{"key":"2453_CR2","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke C, Bachmann A, Descazeaud A et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67:1099\u20131109","journal-title":"Eur Urol"},{"key":"2453_CR3","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2015.12.048","volume":"70","author":"M Gacci","year":"2016","unstructured":"Gacci M, Andersson KE, Chapple C et al (2016) Latest Evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 70:124\u2013133","journal-title":"Eur Urol"},{"key":"2453_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.eururo.2015.12.034","volume":"69","author":"F Fusco","year":"2016","unstructured":"Fusco F, Palmieri A, Ficarra V et al (2016) \u03b11-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol 69:1091\u20131101","journal-title":"Eur Urol"},{"key":"2453_CR5","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.juro.2014.11.094","volume":"193","author":"M Oelke","year":"2015","unstructured":"Oelke M, Shinghal R, Sontag A, Baygani SK, Donatucci CF (2015) Time to onset of clinically meaningful improvement with tadalafil 5\u00a0mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. J Urol 193:1581\u20131589","journal-title":"J Urol"},{"key":"2453_CR6","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.juro.2008.06.079","volume":"180","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG, McVary KT, Elion-Mboussa A et al (2008) Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180:1228\u20131234","journal-title":"J Urol"},{"key":"2453_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.eururo.2011.08.005","volume":"60","author":"H Porst","year":"2011","unstructured":"Porst H, Kim ED, Casab\u00e9 AR et al (2011) Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 60:1105\u20131113","journal-title":"Eur Urol"},{"key":"2453_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.urology.2008.06.060","volume":"73","author":"JA Bittencourt","year":"2009","unstructured":"Bittencourt JA, Tano T, Gajar SA et al (2009) Relaxant effects of sildenafil on the human isolated bladder neck. Urology 73:427\u2013430","journal-title":"Urology"},{"key":"2453_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.urology.2014.02.063","volume":"84","author":"GM Pinggera","year":"2014","unstructured":"Pinggera GM, Frauscher F, Paduch DA et al (2014) Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial. Urology 84:412\u2013419","journal-title":"Urology"},{"key":"2453_CR10","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/nau.22732","volume":"35","author":"Y Kawai","year":"2016","unstructured":"Kawai Y, Oka M, Yoshinaga R et al (2016) Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction. Neurourol Urodyn 35:444\u2013449","journal-title":"Neurourol Urodyn"},{"key":"2453_CR11","doi-asserted-by":"publisher","first-page":"E259","DOI":"10.1111\/j.1464-410X.2012.11255.x","volume":"110","author":"T Minagawa","year":"2012","unstructured":"Minagawa T, Aizawa N, Igawa Y et al (2012) Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein-induced hyperactivity of these nerves. BJU Int 110:E259\u2013E266","journal-title":"BJU Int"},{"key":"2453_CR12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/pros.22686","volume":"73","author":"L Vignozzi","year":"2013","unstructured":"Vignozzi L, Gacci M, Cellai I et al (2013) PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate 73:1391\u20131402","journal-title":"Prostate"},{"key":"2453_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/pros.22584","volume":"73","author":"A Morelli","year":"2013","unstructured":"Morelli A, Comeglio P, Filippi S et al (2013) Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate 73:428\u2013441","journal-title":"Prostate"},{"key":"2453_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1442-2042.2012.03130.x","volume":"20","author":"O Yokoyama","year":"2013","unstructured":"Yokoyama O, Yoshida M, Kim SC et al (2013) Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Int J Urol 20:193\u2013201","journal-title":"Int J Urol"},{"key":"2453_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1757-5672.2011.00088.x","volume":"3","author":"SC Kim","year":"2011","unstructured":"Kim SC, Park JK, Kim SW et al (2011) Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control. Low Urin Tract Symptoms 3:86\u201393","journal-title":"Low Urin Tract Symptoms"},{"key":"2453_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/iju.13489","volume":"25","author":"Y Matsukawa","year":"2018","unstructured":"Matsukawa Y, Majima T, Matsuo K et al (2018) Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a urodynamic-based study. Int J Urol 25:246\u2013250","journal-title":"Int J Urol"},{"key":"2453_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"2453_CR18","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/nau.10066","volume":"21","author":"W Sch\u00e4fer","year":"2002","unstructured":"Sch\u00e4fer W, Abrams P, Liao L et al (2002) Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 21:261\u2013274","journal-title":"Neurourol Urodyn"},{"key":"2453_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/iju.12438","volume":"21","author":"Y Matsukawa","year":"2014","unstructured":"Matsukawa Y, Gotoh M, Kato M et al (2014) Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study. Int J Urol 21:826\u2013830","journal-title":"Int J Urol"},{"key":"2453_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.urology.2015.11.010","volume":"88","author":"Y Matsukawa","year":"2016","unstructured":"Matsukawa Y, Takai S, Funahashi Y et al (2016) The change of testosterone secretion during the treatment of alpha-1 blocker in patients with benign prostatic hyperplasia. Urology 88:149\u2013154","journal-title":"Urology"},{"key":"2453_CR21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.juro.2009.11.014","volume":"183","author":"R Dmochowski","year":"2010","unstructured":"Dmochowski R, Roehrborn C, Klise S et al (2010) Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 183:1092\u20131097","journal-title":"J Urol"},{"key":"2453_CR22","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","volume":"61","author":"M Oelke","year":"2012","unstructured":"Oelke M, Giuliano F, Mirone V et al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61:917\u2013925","journal-title":"Eur Urol"},{"key":"2453_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.eururo.2013.10.015","volume":"65","author":"NI Osman","year":"2014","unstructured":"Osman NI, Chapple CR, Abrams P et al (2014) Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol 65:389\u2013398","journal-title":"Eur Urol"},{"key":"2453_CR24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.juro.2012.07.141","volume":"189","author":"M Nomiya","year":"2013","unstructured":"Nomiya M, Burmeister DM, Sawada N et al (2013) Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol 189:754\u2013761","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2453-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-018-2453-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-018-2453-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T17:31:52Z","timestamp":1566927112000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-018-2453-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,18]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2453"],"URL":"https:\/\/doi.org\/10.1007\/s00345-018-2453-x","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,18]]},"assertion":[{"value":"17 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The ethics committee of the Nagoya University Graduate School of Medicine approved this study protocol (IRB approval number: 2015-0106).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study before enrollment. The study was registered at  as UMIN000017925.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}